Bavarian Nordic gets additional $32M to provide smallpox vaccine to US stockpile
This article was originally published in Scrip
Executive Summary
Danish vaccines developer Bavarian Nordic will have its coffers boosted with a $32 million extension to a 2007 US contract covering its smallpox vaccine Imvamune. The US Department of Health and Services is stockpiling 20 million doses of the vaccine as part Project BioShield, which will underpin any US response to a smallpox emergency and is a component of the US Strategic National Stockpile. The amendment to the contract now brings the total value of the arrangement to $544 million.